

**MINUTES OF THE 41ST PLENARY MEETING OF THE
SCIENTIFIC PANEL ON DIETETIC PRODUCTS, NUTRITION AND ALLERGIES
HELD FROM 28 TO 30 JUNE 2011**

PARTICIPANTS

Panel members:

- Carlo Agostoni
- Jean-Louis Bresson
- Susan Fairweather Tait
- Albert Flynn
- Ines Golly
- Hannu Korhonen
- Martinus Løvik
- Rosangela Marchelli
- Ambroise Martin
- Bevan Moseley
- Monika Neuhäuser-Berthold
- Hildegard Przyrembel
- Seppo Salminen
- Yolanda Sanz
- Sean Strain
- Inge Tetens (only via a Teleconference)
- Daniel Tomé
- Hendrik van Loveren
- Hans Verhagen

EFSA staff:

- Juliane Kleiner
- Reinhard Ackerl
- Kinga Wanda Adamaszwili
- Maria Astridou
- Anja Bronstrup
- Janusz Ciok
- Agnès De Sesmaisons-Lecarre
- Céline Dumas
- Wolfgang Gelbmann
- Leng Heng
- Ilkka Ojansivu
- Danai Papanastasiou
- Ariane Titz
- Emanuela Turla
- Silvia Valtueña Martínez

European Commission:

- Noel Griffin (European Commission)
- Sabine Osaer (European Commission)

1. WELCOME, APOLOGIES FOR ABSENCE

The Chair welcomed all participants to the plenary meeting. Apologies were received from Pagona Lagiou, Stephan Strobel and Inge Tetens. The Chair also welcomed Ilkka Ojansivu recently joining the NDA secretariat for traineeship.

2. ADOPTION OF THE AGENDA AND THE MINUTES OF LAST PLENARY

The agenda of the meeting and the minutes of the 40th Plenary meeting were adopted.

3. DECLARATIONS OF INTEREST

EFSA Secretariat screened the Annual Declaration of interest (ADoI) and Specific Declaration of interest (SDoI) filled in by the scientific experts invited to this meeting in accordance with EFSA's Policy on Declarations of Interests.

For the Agenda item related to application from Kraft Foods - "Biscuits for breakfast", Albert Flynn declared an interest and withdrew from the chair and refrained from discussion for this agenda item.

For the Agenda item related to an application from Valio - "Peptides isoleucyl-prolyl-proline (IPP) and valyl-prolyl-proline (VPP)", Seppo Salminen and Hannu Korhonen declared an interest and refrained from discussion for this Agenda item.

With regard to the other items on the agenda for this meeting no conflicts of interests have been identified during the screening process or at the beginning of this meeting.

4. FEEDBACK FROM EFSA SCIENTIFIC COMMITTEE AND OTHER EFSA PANELS, GENERAL INFORMATION FROM EFSA

The Scientific Committee endorsed three draft documents for public consultation: guidance on repeated-dose 90-day oral toxicity study on whole food/feed in rodents (<http://www.efsa.europa.eu/en/consultations/call/110707.htm>), guidance on default values (<http://www.efsa.europa.eu/en/consultations/call/110707a.htm>), and opinion on threshold of toxicological concern (<http://www.efsa.europa.eu/en/consultations/call/110712a.htm>). The Draft guidance on statistical significance and biological relevance will be subject for endorsement by written procedure prior to release for public consultation.

EFSA has also launched a public consultation of its draft Policy on Independence and Scientific Decision-Making Processes (<http://www.efsa.europa.eu/en/consultations/call/110707b.htm>).

The Panel was briefed about the results of the EFSA Scientific Expert Satisfaction Survey, which was launched in February 2011, to evaluate experts' overall satisfaction in relation to working with EFSA and particularly with regard to the administrative, scientific and communication support provided by the Authority.

The Panel was also informed about the status of the call launched by EFSA to renew the membership and create reserve lists for its Scientific Panels and Scientific Committee for the upcoming three-year period from mid-2012 to mid-2015. The evaluation procedure and the timeline were explained.

The Panel were kindly reminded to inform the secretariat about invitations/participations to conferences organised by stakeholders in the areas of the Panel activities.

5. FEEDBACK FROM THE COMMISSION ON MATTERS RELATING TO THE PANEL

The Commission provided feedback on the status of the Commission Decision related to the opinions that were adopted by the Panel between January-June 2011, including the opinions concerning Art 13(1), Art 14 and 13(5) claims. All the adopted Commission decisions are available on the Commission website: http://ec.europa.eu/food/food/labellingnutrition/claims/community_register/index_en.htm.

Related to Art 13(1) health claims, the Commission provided feedback from its ad-hoc working group meeting with Member States about the discussion on opinions adopted by the Panel, and the procedure/timeline of those claims that were subject for further assessment (probiotics not sufficiently characterised, claims for which EFSA concluded that there is insufficient evidence).

6. NEW REQUESTS

The Panel was informed about new requests received from the Commission to EFSA for scientific opinions related to the following:

- **Advice in relation to the authorisation procedure for a health claim on “Toothkind” drinks** (see also item 11)
- **Safety in use of omega-3 long chain polyunsaturated fatty acids (DHA, EPA, DPA)**
- **Labelling exemption regarding lysozyme used in wine**

In addition, EFSA has issued a self-mandate for the Panel to deliver an opinion (a statement) on the **Safety of glucosamine for patients receiving coumarin anticoagulants**, which was not addressed in the published Novel Food opinion related to glucosamine.

The Panel confirmed the rapporteurs dealing with these new requests.

7. NOVEL FOODS

7.1. “Safety of Glavonoid®” (EFSA-Q-2009-00749)

The draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The text of the full opinion is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2287.htm>.

8. GENERAL ISSUES ON HEALTH CLAIM EVALUATION

8.1 Update on Article 13(5) and 14 applications

The Secretariat informed the Panel about the status of claims applications since the last Plenary meeting.

Article 14 claims: Since the last meeting, four new applications were received referring to disease risk reduction claims (CranPureTM & reducing adhesion of *E. coli* on the walls of urinary tract, a risk factor for urinary tract infection; Protein-rich soybean component and lower blood cholesterol; two applications related to Barley beta-glucan and lower blood cholesterol). By 15 June 2011, EFSA had received 273 Article 14 applications (218 referring to children’s health and development and 55 referring to reduction of disease risk claims); 6 applications were under evaluation, 110 applications were withdrawn.

Article 13(5) claims (claims based on newly developed science and/or which include a request for the protection of proprietary data): Since the last meeting, two new applications were received (DAG oil and management of body weight; Coffee C21 and maintenance of DNA integrity in cells of the body). By 15 June 2011, EFSA had received 52 applications under Article 13(5); 7 are under evaluation, 29 were adopted, 14 were withdrawn, and 2 were under validation.

Rapporteurs have been appointed for the new applications received.

8.2 Update on Article 13 list claims

Some remaining editorial issues related to adopted Art. 13 claims opinions were discussed and clarified.

With the publication of the fifth series of Article 13(1) claims opinions on 30 June 2011, EFSA adds an additional 536 claims to the 2,187 claims published to date. The next series of publication of adopted Article 13 opinions is foreseen by July 2011, which comprises all claims that have been adopted at this June Plenary meeting (see items 10).

The Secretariat took the opportunity to express EFSA's great gratitude to the Panel members for their excellent scientific contribution, their continuous support and high commitment during the whole process of Article 13(1) health claims evaluations.

9. APPLICATIONS PURSUANT TO ARTICLES 14/13(5) OF REGULATION (EC) NO 1924/2006

9.1 “*L. delbrueckii* subsp. *bulgaricus* AY/CSL (LMG P-17224) and *S. thermophilus* 9Y/CSL (LMG P-17225)” and “modulate intestinal microflora” (Art.14_children: 0143_IT, EFSA-Q-2008-273)

The draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2288.htm>.

9.2 “Beta-Palmitate” and “increased calcium absorption” (Art. 14: 0092_FR, EFSA-Q-2008-172)

The draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2289.htm>.

9.3 “L-tyrosine” and “essential for the natural formation of dopamine” (Art. 13.5: 0298_UK, EFSA-Q-2011-00319)

The draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2290.htm>.

9.4 Collagen hydrolysate and “maintenance of joint health” (Art. 13(5): 0297_DE: EFSA-Q-2011-00201)

The draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2291.htm>.

9.5 “Biscuits for breakfast” and “appearance in the blood circulation of exogenous glucose from biscuits consumed for breakfast that is moderate and stable throughout the morning” (Art 13.5: 0284_BE, EFSA-Q-2010-00966)

The draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The text of the full opinion is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2292.htm>.

9.6 “Peptides isoleucyl-prolyl-proline (IPP) and valyl-prolyl-proline (VPP)” and “helps to maintain normal blood pressure” (Art. 13(5): 0295_FI, EFSA-Q-2011-00121)

The Applicant’s responses to EFSA request for supplementary information were discussed. A revised draft opinion will be discussed at the next Working group Claims meeting.

10. DRAFT ARTICLE 13(1) OPINIONS

The Panel discussed and adopted the remaining Article 13(1) claims related to:

- 10.1 Creatine and physical performance (ID 739, 1520, 1521, 1522, 1523, 1525, 1526, 1527, 1531, 1532, 1533, 1534, 1535, 1922, 1923, 1924, 1963).** The full text of the opinion is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2303.htm>.
- 10.2 Monascus purpureus (red yeast rice) and maintenance of LDL-cholesterol (ID 1648, 1700).** The full text of the opinion is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2304.htm>.
- 10.3 Sodium and potassium salts of citric acid and maintenance of normal bone (ID 330).** The full text of the opinion is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2302.htm>.
- 10.4 Carbonate/bicarbonate salts of sodium and potassium and maintenance of normal bone (ID 331, 1402).** The full text of the opinion is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2301.htm>.
- 10.5 Soy isoflavones and post-menopausal symptoms (ID 1654, 1704b, 2140, 3093b, 3154, 3590).** The full text of the opinion is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2264.htm>.

More details on the claims adopted are available on the EFSA register of Questions:

<http://registerofquestions.efsa.europa.eu/roqFrontend/questionsListLoader?panel=NDA&foodsectorar ea=26>

11. DRAFT STATEMENT ON A COMMISSION REQUEST FOR ADVICE RELATED TO “TOOTHKIND” (EFSA-Q-2011-00781)

A draft statement was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text is published in the EFSA Journal: <http://www.efsa.europa.eu/en/efsajournal/pub/2293.htm>.

12. DRAFT GUIDANCE ON THE REQUIREMENTS FOR HEALTH CLAIMS RELATED TO NEUROLOGICAL AND PSYCHOLOGICAL FUNCTIONS (EFSA-Q-2010-01185)

The discussion of this agenda item was postponed to next Plenary meeting.

13. ANY OTHER BUSINESS

The minutes of the 41st Plenary meeting were adopted on 14 September 2011.